Acetazolamide Per os for Decompensation of Heart Failure

NCT ID: NCT05802849

Last Updated: 2024-11-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-01
• Study Completion Date: 2025-12-01

Brief Summary

The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually.

Acute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.

Detailed Description

Chronic heart failure (CHF) is a syndrome caused by a violation of the heart's ability for contraction and relaxation, which is associated with an imbalance of vasoconstrictor and vasodilating neurohormonal systems, leading to hypoperfusion of organs and systems and the appearance of such complaints and signs as shortness of breath, weakness, palpitations, increased fatigue, swelling due to fluid congestion in the body.

An unfavorable prognosis, significant costs associated with excessive hospitalization of patients with this diagnosis require the development of clear criteria for the diagnosis and treatment of this condition. The variety of variants of the course of the disease, heterogeneous clinical characteristics of patients, difficulties in determining predisposing factors, unsufficient data on the pathogenetic features of the development of certain types of decompensation of CHF require an active scientific search in this direction and the development of modern clinically effective algorithms for the diagnosis and treatment of such patients The scientific hypothesis of the present study is that the use of acetazolamide in patients with decompensated HF at the hospital stage is accompanied by a significant regression of congestion compared to standard diuretic therapy (since randomization).

The investigators will anticipate that appointment of acetazolamide is accompanied by a decrease in the manifestation of edema syndrome.

Conditions

Chronic Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

a group with the use of acetazolamide

acetazolamide is prescribed at a dose of 250 mg 3 times a day

Group Type: EXPERIMENTAL

Acetazolamide

Intervention Type: DRUG

Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.

a group of standart therapy

standart therapy includes main and additional medicine for treatment of chronic heart failure

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Acetazolamide

Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.

Intervention Type: DRUG

Other Intervention Names

diacarb

Eligibility Criteria

Inclusion Criteria

• Men or women aged 18 years and older
• Decompensated CHF NYHA II-IV, which required intravenous administration of diuretics
• Any injection fraction of left ventricle*
• Signed informed consent to participate in the study.

• in patients with LV LV ≥ 50%: the presence of structural changes of the heart# (left ventricular myocardial hypertrophy, enlargement of the left atrium) and/or diastolic dysfunction# and/or increased levels of BNP or NT-proBNP (BNP > 400 pg/ml or NT-proBNP > 450 pg/ml in persons younger 50 years old; > 900 pg/l in persons 51-75 years old; > 1800 pg/ml older than 75 years) #.

• criteria according to clinical guidelines 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083

Exclusion Criteria

• Acetazolamide therapy for a month before hospitalization.
• The expected intravenous use of inotropes, vasopressors or sodium nitroprusside at any time of the study.
• Exposure to nephrotoxic agents (e.g. contrast dye) is expected within the next 3 days.
• Hypersensitivity to acetazolamide, other sulfonamides and / or components of the drug.
• Systolic blood pressure <90 mmHg.
• Pregnancy and lactation.
• Hypokalemia (potassium < 3.5 mmol/l).
• Hyponatremia (sodium <135 mmol/l).
• Severe chronic renal insufficiency (creatinine clearance less than 10 ml/min) or the use of renal replacement therapy or ultrafiltration at any time prior to inclusion in the study.
• Metabolic acidosis (bicarbonate less than 12 mmol/L).
• Severe anemia (Hb <70 g/L).
• Acute renal failure.
• Addison's disease.
• Decompensated diabetes mellitus.
• Emergency conditions (myocardial infarction, pulmonary embolism, acute myocarditis, pericarditis, aortic aneurysm).
• Cirrhosis of the liver with encephalopathy and liver failure.
• Congenital heart defects.
• Malignant neoplasm in the phase of active treatment or terminal form of cancer.
• Hypocorticism.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Samara State Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dmitriy Duplyakov

Role: PRINCIPAL_INVESTIGATOR

SamSMU

Locations

Samara state medical university

Samara, , Russia

Site Status: RECRUITING

Countries

Russia

Central Contacts

Dmitriy Duplyakov, MD

Role: CONTACT

Duplyakov@yahoo.com

89277297273

Olesya Rubanenko, MD

Role: CONTACT

olesya.rubanenko@gmail.com

89371887780

Facility Contacts

Olesya Rubanenko

Role: primary

olesya.rubanenko@gmail.com

89371887780

Other Identifiers

001

Identifier Type: -

Identifier Source: org_study_id